Analyst Consensus ?
ConsensusBuy14 ratings
Bullish1071.4%
Neutral321.4%
Bearish17.2%
FN2 Earnings Intelligence
West Pharmaceutical Services, Inc. analyst ratings
West Pharmaceutical Services, Inc. (WST) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$339.59Current
$250Low
$354.08Average
$447High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 27, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 9, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Jul 2, 2026 |
| Barclays | Overweight | Equal Weight | Upgrade | Jun 9, 2026 |
| Stephens & Co. | Overweight | Overweight | Maintain | Jun 2, 2026 |
| UBS | Buy | Buy | Maintain | Oct 24, 2025 |
| B of A Securities | Buy | Buy | Maintain | Dec 13, 2024 |
| Jefferies | Buy | Hold | Upgrade | Feb 7, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Dec 14, 2022 |
| Bank of America | Underperform | Neutral | Downgrade | Dec 12, 2019 |
| William Blair | Outperform | Outperform | Maintain | Apr 23, 2019 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jan 24, 2018 |
| Wells Fargo | Outperform | Outperform | Maintain | Oct 27, 2017 |
| Janney Capital | Buy | Buy | Maintain | Jan 8, 2016 |
Named analyst price targets
Upside is calculated against the persisted current price $339.59. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Evercore ISI | Analyst unavailable | $425 | $333.12 | +25.2% | Jul 27, 2026 |
| BNP Paribas | Analyst unavailable | $447 | $353.71 | +31.6% | Jul 13, 2026 |
| Morgan Stanley | Analyst unavailable | $365 | $353.68 | +7.5% | Jul 9, 2026 |
| Evercore ISI | Daniel Markowitz | $410 | $359.27 | +20.7% | Jul 6, 2026 |
| KeyBanc | Analyst unavailable | $390 | $365 | +14.8% | Jul 2, 2026 |
| Barclays | Luke Sergott | $400 | $319.75 | +17.8% | Jun 9, 2026 |
| Morgan Stanley | Analyst unavailable | $315 | $306.39 | -7.2% | Apr 27, 2026 |
| Barclays | Analyst unavailable | $310 | $306.16 | -8.7% | Apr 27, 2026 |
| UBS | Dan Leonard | $340 | $246.6 | +0.1% | Feb 13, 2026 |
| Deutsche Bank | Analyst unavailable | $315 | $247.49 | -7.2% | Feb 13, 2026 |
| Barclays | Luke Sergott | $265 | $243.61 | -22.0% | Feb 13, 2026 |
| Jefferies | David Windley | $295 | $249.97 | -13.1% | Feb 10, 2026 |
| Evercore ISI | Daniel Markowitz | $320 | $237.88 | -5.8% | Feb 3, 2026 |
| Morgan Stanley | Analyst unavailable | $285 | $274.14 | -16.1% | Dec 1, 2025 |
| Barclays | Analyst unavailable | $325 | $293.62 | -4.3% | Oct 27, 2025 |
| UBS | Dan Leonard | $355 | $307.25 | +4.5% | Oct 24, 2025 |
| Deutsche Bank | Justin Bowers | $345 | $304.74 | +1.6% | Oct 24, 2025 |
| Evercore ISI | Daniel Markowitz | $390 | $309.28 | +14.8% | Oct 23, 2025 |
| Evercore ISI | Analyst unavailable | $350 | $268.07 | +3.1% | Oct 7, 2025 |
| Barclays | Analyst unavailable | $275 | $271.42 | -19.0% | Oct 2, 2025 |
| Redburn Partners | Jamie Clark | $311 | $257.53 | -8.4% | Sep 15, 2025 |
| Barclays | Luke Sergott | $245 | $222.68 | -27.9% | Jun 24, 2025 |
| Jefferies | David Windley | $393 | $287.85 | +15.7% | Nov 19, 2024 |
| Jefferies | David Windley | $536 | $413 | +57.8% | Feb 7, 2024 |
| Deutsche Bank | Analyst unavailable | $250 | $251.9 | -26.4% | Dec 14, 2022 |
| UBS | Analyst unavailable | $250 | $222.84 | -26.4% | Nov 30, 2022 |
Track every rating change on WST the moment it posts. Free to start.
Start free